Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare Biotechnology

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > BRISTOL Myers squib discussing on CNBC its’ acquisition

<< Previous

Bullboard Posts

Next >>

Comment by Chianchinon Jun 03, 2022 5:03pm

105 Views

Post# 34730810

RE:BRISTOL Myers squib discussing on CNBC its’ acquisition

These clones aliases would like you to beleive and imply that GUD is developing new drugs. GUD is a re-seller of expired generics drugs in lATAM they sell these drugs at a huge discound and near impossible to make a profits guven worthless LATAM currencies. It is not a coincidence that the market values GUD at $5 only because GUD is the only few buyers left or it would be at $3

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season